Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies. The company was incorporated in 1987 and is headquartered in Foster City, California.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Gilead Sciences, Inc. has announced plans to cut more than 100 jobs in the Bay Area. This decision reflects the company's ongoing efforts to streamline operations and adjust its workforce in response to current market conditions. The layoffs are part of a broader strategy to enhance efficiency and focus on key business areas. While specific departments affected were not disclosed, the cuts are expected to impact various roles within the organization. Gilead's commitment to maintaining its core operations remains a priority as it navigates these changes.
Gilead Sciences, Inc. has announced plans to lay off employees associated with Arcellx in California and Maryland, with the layoffs set to begin in 2026. While the exact number of employees affected has not been disclosed, the company's decision indicates a significant workforce adjustment. The layoffs are part of a broader restructuring strategy, although specific reasons for this decision have not been detailed in the article. The announcement highlights Gilead's ongoing efforts to streamline operations amid changing market conditions.
Gilead Sciences, Inc., a prominent biotech company based in the Bay Area, has announced the layoff of 108 employees at its Redwood City facility. This decision reflects ongoing adjustments within the company as it navigates the current market landscape. The layoffs are part of a broader strategy to streamline operations and enhance efficiency. Gilead's workforce reduction is indicative of challenges faced in the biotech sector, as companies reassess their staffing needs in response to changing economic conditions. The layoffs are set to take effect immediately, impacting various roles within the organization.
Gilead Sciences, Inc. has laid off approximately 100 employees from its subsidiary, Arcellx, as part of a strategic restructuring. The layoffs were announced as Gilead aims to streamline operations and focus on its core business areas. This decision reflects the company's ongoing efforts to optimize its workforce in response to market conditions. The affected employees were primarily involved in research and development roles, which Gilead is now scaling back. The layoffs took effect on October 1, 2023, marking a significant shift in Gilead's operational strategy.
Gilead Sciences, Inc. has announced another round of layoffs, affecting approximately 300 employees in its Foster City, California location. This decision comes just seven months after the company previously laid off staff, indicating ongoing challenges within the biotech sector. The layoffs are part of a broader restructuring effort aimed at streamlining operations and reducing costs. Gilead has faced pressures from market dynamics and is adjusting its workforce to better align with its strategic goals. The company continues to navigate a competitive landscape while focusing on its core business areas.
Gilead Sciences, Inc. has announced significant job cuts, affecting approximately 500 employees at its Foster City, California location. This decision comes as part of a broader restructuring effort aimed at streamlining operations and reducing costs amidst challenging market conditions. The layoffs are part of Gilead's strategy to focus on its core business areas and improve overall efficiency. The company has faced pressure from investors and market dynamics, prompting this workforce reduction. The layoffs are expected to take effect immediately, impacting various departments within the organization.
Gilead Sciences, Inc., a major HIV drug manufacturer, is set to lay off nearly 150 employees in the Bay Area. This decision comes as part of a broader restructuring effort aimed at streamlining operations and reducing costs. The layoffs are expected to take effect shortly, impacting various roles within the company. Gilead's leadership has indicated that these cuts are necessary to align with the company's strategic goals and respond to market dynamics. The affected employees will be notified soon, and the company is committed to providing support during this transition.
Gilead Sciences, Inc. has laid off 36 employees following the decision to cancel its expansion plans in Oceanside, California. This move reflects the company's strategic adjustments in response to changing business conditions. The layoffs are part of a broader reevaluation of Gilead's operational strategies, although specific details about the affected departments were not disclosed. The company aims to streamline its operations while focusing on its core business objectives. The layoffs occurred on October 1, 2023, marking a significant shift in Gilead's workforce management.
Gilead Sciences, Inc. is set to lay off dozens of employees in Rockville, Maryland, following its acquisition of Arcellx. The layoffs are part of the company's restructuring efforts post-acquisition. While the exact number of affected employees is not specified, it is reported that approximately 36 positions will be eliminated. The decision reflects Gilead's strategic adjustments as it integrates Arcellx into its operations. Further details on the timeline for these layoffs have not been disclosed.
Gilead Sciences, Inc. is set to lay off nearly 200 workers as a result of its acquisition of Arcellx. The layoffs are part of the company's restructuring efforts following the completion of the acquisition. While specific details regarding the affected locations or departments were not disclosed, the decision reflects Gilead's strategic adjustments in response to the new operational landscape post-acquisition. The layoffs are anticipated to occur after the acquisition closes, although an exact date has not been provided. This move underscores Gilead's ongoing efforts to streamline its workforce in alignment with its business objectives.
No one has shared a story from Gilead Sciences, Inc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.